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Introduction
Owing to the variability of influenza viruses, vaccines 
need to be up-dated annually. Particularly, subjects at 
risk must be vaccinated every year. However, many var-
iables may influence vaccine efficacy, such as matching 
with circulating viruses, age, concomitant pathologies, 
etc. Influenza vaccines are therefore considered to have 
a suboptimal efficacy profile. For these reasons, many 
improvements, such as the addition of adjuvants, have 
been made in recent years. Researchers have long been 
trying to develop a safe and effective live attenuated 
influenza vaccine. Indeed, considerable attention has 
recently been devoted to the challenge of generating ef-
fective immune responses at mucosal surfaces. Mucos-
al surfaces are sites of pathogen entry and replication, 
making immune responses at these locations critical for 
effective immunity [1].
Candidate influenza vaccines delivered intranasally 
and inducing mucosal immunity include live attenu-
ated viruses [2], adjuvated killed vaccines [3, 4], and 
recombinant viral vectors [5]. Live attenuated vac-
cines are prepared through the reassortment of a donor 
(master) strain with lesions in internal antigen genes 
and an epidemic strain. Three approaches have been 
attempted with the aim of creating a suitable vaccine, 
namely: developing temperature-sensitive (ts) mutants 
by treatment with 5-fluorouracil [6], selecting host-
range variants by adaptation in non-human cells [7], 
and adapting the influenza virus to grow at low tem-
perature [8-10].
Immunoresponse against Influenza viruses
In most developed countries, inactivated egg-derived 
vaccines are currently used. However, these have some 
drawbacks, such as low efficacy in the elderly and in the 
event of pandemics. Furthermore, the acceptance of an 
inactivated influenza vaccine (IIV) may be conditioned 
by their intramuscular administration, particularly in 
children. The aim of vaccination with a live attenuated 
virus is to induce a secretory and systemic immune re-
sponse that more closely resembles the immune response 
detected after natural infection.
Resistance to influenza virus infection is due to both 
mucosal and systemic immunity [11-14]. Moreover, an-
tibodies generated locally in the upper airways consti-
tute the main defence against natural contagion [12-14]. 
While secretory immunoglobulin A (SIgA) is involved in 
the defence of the upper respiratory tract, serum immu-
noglobulin G (IgG) protects the lower airways. Sponta-
neous infection may confer long-term immunity against 
influenza viruses [15]. In addition, the cell-mediated im-
mune response is principally responsible for eliminating 
virus-infected cells, thus facilitating recovery from the 
disease. Human infection generates antibodies against 
all the most important viral antigens [16-17]. Whereas 
antibodies against the inner components, matrix protein 
(M) and nucleoprotein (NP), are not protective [18], 
antibodies against hemagglutinin (HA) and neuroami-
nidase (NA) are associated with resistance to infection. 
As most microorganisms enter the human body through 
mucosal tissue, the local immune system constitutes the 
first line of defence against infection, together with in-
nate immunity. On first infection, immunoglobulin M 
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Summary
Owing to the variability of influenza viruses, vaccine composition 
needs to be up-dated annually. As many variables can influence 
their efficacy, vaccines are still considered “sub-optimal”. Many 
studies have been carried out in recent years to improve vaccines. 
In particular, researchers and vaccine-producing corporations 
have focused on developing a live vaccine.
Among the candidate vaccines, the strain developed by Maassab 
has recently been licensed in the USA and Europe, after exten-
sive investigation. This vaccine is safe and well tolerated, and 
has shown very good genetic stability. Although vaccine recipi-
ents are able to spread the virus, transmission to close contacts is 
practically non-existent.
Studies on cold-adapted attenuated influenza vaccines have 
demonstrated that such vaccines are effective, and sometimes 
more effective than inactivated influenza vaccines. Cold-adapted 
attenuated influenza vaccines therefore appear to be an important 
weapon against influenza. However, a more widespread use of 
these vaccines is to be recommended, especially in children, as 
the more acceptable way of administration can favour parental 
compliance.
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(IgM), IgG and immunoglobulin A (IgA) against HA 
are present in nasal secretions [11-19]. While IgGs are 
derived as a serum transudate, IgA and IgM are gener-
ated locally. Resistance to influenza viruses or disease is 
linked with the amount of local and/or serum antibody 
against HA and NA [18].
The killing of influenza-infected cells is caused by cy-
totoxic T cells (CTLs), jointly with influenza-specific 
antibodies and complement [20-23]. Influenza infection 
elicits a robust T-helper response, which has a valuable 
function in rousing antibody production against the vi-
rus [24, 25].
Historical remarks
More than 40 years have passed since the first cold-
adapted influenza viruses were developed in Russia as 
potential live attenuated vaccines.
Therefore, the strategy of creating live influenza vac-
cines has been developed around a two-step process. 
The first phase requires the creation of so-called ‘master 
strains’ of attenuated vaccines. Once acceptable ‘master 
strains’ are available, this stage rarely needs to be re-
peated. The second phase involves the genetic transfer 
of the attenuation characteristics from the older ‘mas-
ter strains’ to newer variants that emerge from the lat-
est outbreaks. This phase would needs to be constantly 
repeated in a reproducible manner, in order to update the 
vaccine [26]. Development of the Russian live attenuat-
ed ‘master strains’ began with much the same traditional 
approach as for most other already used live vaccines. 
This involved repeated passages of an initial virus be-
lieved to represent the ‘wild-type’ in the laboratory host 
system, with a view to selecting a less virulent strain.
Smorodincev [27] and Alexandrova et al. [8] were the 
key Russian scientists who developed the cold-adapted 
‘master strains’ [26]. Wild-type virus isolates were pas-
saged in embryonate eggs at successively lower temper-
atures than that normally used for their replication in the 
laboratory. Finally, viruses were produced which grew 
well at a temperature of 25°C, whereas the parent virus 
hardly grows at all at this temperature.
Researchers in the USA have demonstrated the feasibili-
ty of live cold-adapted vaccine preparation. The vast ma-
jority of clones recovered from mixed infections (donor 
and wild-strain) in which selective measures were used, 
as described above, were found to have only the HA and 
NA genes from the wild-type virus, but the other 6 genes 
from the cold-adapted parent (‘6-2’ gene composition). 
This work was originally carried out by comparing the 
mobility of individual nucleic acid segments during gel 
electrophoresis; now, however, it can be done by apply-
ing polymerase chain reaction methods. Such ‘6-2’ reas-
sortant viruses retain the properties of growing well at 
25°C and poorly at 39°C, as is the case with their attenu-
ated parent; however, they contain the surface antigens 
of new epidemic strains.
Among cold-adapted strains, the best strains were de-
veloped by Maassab [9]. Before 1967, the attenuation 
of influenza viruses was achieved through a gradual 
process of cold adaptation. Subsequently, Maassab 
et al. optimized attenuation by abruptly reducing the in-
fluenza virus cultivation temperature from 35 to 25°C. 
In this way, adaptation took place in weeks instead of 
6-8 months [28]. An attenuated Hong Kong strain of 
influenza virus (A2/Aichi/2/68) was successfully used 
in clinical trials by Maassab et al. [28]. After this re-
search, many other studies were carried out using the 
cold-adapted influenza virus [29, 30], until a cooperative 
program among vaccine evaluation units that was spon-
sored by the National Institute of Allergy and Infectious 
Diseases (NIAID) brought these vaccines to complete 
development by Wyeth-Ayerst Laboratories (Philadel-
phia, PA) [26].
Safety and tolerability
Maassab’s study, which was published in 1969, reported 
that the A2/Aichi/2/68 cold-adapted attenuated influen-
za virus was genetically stable, safe and well tolerated 
in mice, ferrets and humans [29]. Subsequently, Murphy 
et al. repeatedly demonstrated [29, 31, 32] that different 
cold-adapted influenza viruses attenuated with the meth-
ods of Maassab and Cox induced only febrile systemic 
illness.
Likewise, Alexandrova et al. demonstrated that two 
recombinant cold-adapted attenuated Influenza A vac-
cines were genetically stable, safe and well tolerated in 
children aged 3-15 years [33].
In 1992, Anderson et al. [30] published the results of 
a clinical trial conducted on children aged 8 months to 
14 years with a cold-adapted influenza B/Texas/84 re-
assortant strain. The virus proved phenotypically stable 
and the study demonstrated the safety of the vaccine. 
Live attenuated, cold-adapted monovalent and bivalent 
influenza A vaccines were evaluated in seronegative in-
fants (6-18 months) by Gruber et al. [34]. The Authors 
observed no excess of fever or respiratory symptoms in 
vaccine recipients than in controls. The following year, 
the same Authors published the results of an analogous 
study [35] conducted on a larger number of subjects 
(1,126 children) with a wider age range (2 months, 3 
years). The vaccine was well tolerated, and fever and 
respiratory symptoms, including rhinorrhea, were not 
statistically more frequent in recipients than in controls.
In 1997, King et al. reported the results of a trial con-
ducted in children aged 18-71 months [36] with vari-
ous doses of a trivalent cold-adapted influenza vaccine 
(CAIV-T) administered intranasally by means of drops 
or spray. The results confirmed that, at all doses, the 
vaccine was safe and well tolerated.
In 1996-1997, Piedra et al. performed a very interest-
ing study on the safety and tolerability of a CAIV-T in 
children aged 15-71 months [37]. They subsequently 
studied the safety of sequential annual doses of CAIV-T 
over a 4-year period in the same cohort of volunteers. 
During the first year of study, 1,602 children were re-
cruited (1,314 received 2 doses and 288 one dose of 
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the attenuated vaccine or placebo in a 2:1 ratio). In the 
second year, 1,358 of the original participants received 
1 dose of vaccine or placebo, according to the original 
treatment. In the third and fourth years, subjects who had 
previously been given the cold-adapted vaccine were re-
quested to receive their 3rd or 4th dose of the vaccine: 
642 and 549 subjects were enrolled, respectively. The 
Authors concluded that CAIV-T was safe in children. 
However, mild respiratory symptoms (particularly run-
ny nose), and gastrointestinal and systemic symptoms of 
short duration were observed in a minority of recipients, 
particularly after the first dose of the vaccine.
In the early 2000s, convincing evidence of the safety 
and efficacy of cold-adapted live influenza vaccines was 
provided by many published papers, notably that of Bey-
er et al., who carried out a meta-analysis of 19 studies 
conducted in the United Kingdom (UK) and USA [38]. 
With regard to safety, these Authors considered 11 clini-
cal trials involving 4,088 subjects, and found that the 
frequency of systemic vaccine reactions ranged from 0 
to 31.6%. In the trials considered, the vaccine recipients 
received an attenuated cold-adapted vaccine or an inac-
tivated influenza vaccine. None of the 11 comparisons 
showed any significant difference between the two vac-
cines.
In 2003, Harper et al. prepared a summary of the rec-
ommendations of the Advisory Committee on Immuni-
zation Practices (ACIP) of the US Center for Diseases 
Control and Prevention (CDC) on the use of the at-
tenuated Influenza vaccine (LAIV) [39]. These Authors 
underlined that the LAIV was approved in the US for 
healthy persons aged 5-49 years only, and subdivided 
the safety data on the basis of the age of the popula-
tion. The symptoms more often reported in vaccinated 
children than in placebo recipients were: runny nose, 
headache, fever, vomiting, abdominal pain and myalgia. 
These symptoms were associated more frequently with 
the first dose and were self-limiting [40, 41]. Neverthe-
less, the Authors pointed out that unpublished data from 
a study including subjects from 1 to 17 years indicated 
an increase of symptoms in the subset of subjects aged 
12-59 months, and that the vaccine should be licensed 
only for children over 60 months of age. Regarding 
adults, Harper et al. emphasized that nasal congestion, 
headache and sore throat had been reported more often 
in vaccine recipients than in placebo recipients [39].
Bergen et al. [42] performed a specific safety study on 
attenuated influenza vaccine on a large sample of chil-
dren and adolescents (12 months-17 years). A total of 
9,689 evaluable subjects were recruited in the clinical 
trial. The conclusions of the Authors were that Cold-
Adapted Influenza Vaccine (CAIV) was generally safe 
in children and adolescents; however, there was an in-
creased risk of asthma/reactive airway disease in chil-
dren < 36 months of age.
In 2004, a paper [43] reported that CAIV-T had been 
evaluated in 20 clinical trials, in which 20,000 subjects 
(more than 15,000 children and adolescents aged 1-17 
years and more than 3,700 healthy adults aged 18-64 
years) had received more than 28,000 doses of vaccine, 
and had been compared with more than 11,300 placebo 
recipients. The Author reported that CAIV had been 
well tolerated in clinical trials with 19 different 6:2 reas-
sortant virus strains, both of type A (H1N1 and H3N2) 
and of type B, and underlined that no severe adverse 
events (SAEs) were associated with vaccination, even 
in infants and children. However, Belshe also reported 
that mild, transient symptoms, such as mild upper res-
piratory signs, low fever and decreased activity, had 
been described more frequently in vaccinated subjects 
than in placebo recipients in several clinical trials. In 
2006, Belshe’s investigation was up-dated by Ambrose 
et al. [44]. These Authors evaluated the results obtained 
in more than 40,000 vaccinated subjects, and confirmed 
the data reported by Belshe.
In 2007, Belshe et al. published a study carried out on 
children aged 6 to 59 months, without a recent episode 
of wheezing illness or severe asthma, who were random-
ly assigned in a 1:1 ratio to receive either cold-adapted 
Trivalent live attenuated Influenza Vaccine or TIV [45]. 
Influenza-like illness was monitored by means of cells 
cultures throughout the 2004-2005 influenza season. 
Safety data were available for 8,352 children. Among 
previously unvaccinated children, wheezing within 42 
days after the administration of dose 1 was more com-
mon with live attenuated vaccine than with inactivated 
vaccine, primarily among children aged 6 to 11 months.
Rates of hospitalization for any cause during the 180 
days after vaccination were higher among the live at-
tenuated vaccine recipients aged 6 to 11 months than 
among the recipients of inactivated vaccine in this age-
group (6.1% vs. 2.6%, p = 0.002).
Recently, Tennis et al. have published the results of a 
post-marketing evaluation of the frequency and safety 
of live attenuated influenza vaccine use in non-recom-
mended children younger than 5 years [46]. The 2007 
US approval for the use of LAIV in children aged 
24-59 months included precautions against use in: 
children < 24 months (cohort 1), children aged 24-59 
months with asthma (cohort 2), and those with recurrent 
wheezing (cohort 3) or altered immunocompetence (co-
hort 4). A post-marketing commitment was initiated to 
monitor LAIV use and the frequency of selected safety 
outcomes in these cohorts. Vaccination rates and the 
frequency of hospitalizations or emergency department 
visits within 42 days after LAIV and TIV administration 
were estimated from health insurance claims from 2007 
to 2009. Rates of LAIV use per 10,000 child-days were 
lower among cohorts 1, 2, and 4 than among the LAIV-
recommended population.
In cohort 3, however, rates of LAIV use per 10,000 
child-days were similar to those of the LAIV-recom-
mended population. The rate of emergency department 
visits/hospitalizations within 42 days of vaccination 
with LAIV was the same as or less than the rate within 
42 days of vaccination with TIV.
A very recent global evaluation of data on the safety 
and tolerability of LAIV was published by Ambrose 
et al. in 2008 (49,000 individuals in 48 completed stud-
ies, including more than 18,000 children younger than 
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5 years) [47]. At that time more than 10 million doses 
had been commercially distributed in the United States 
since licensure. LAIV are intended not only to mitigate 
seasonal influenza, but also to guard against pandemics. 
In this regard, Mallory et. al [48] evaluated the safety, 
tolerability and immunogenicity of a monovalent in-
tranasal 2009 A/H1N1v (A/California/07/09) LAIV in 
children and adults. Solicited symptoms were less fre-
quent after dose 2 in both adults and children, and no 
vaccine-related serious adverse events occurred.
As already mentioned [42], a particular concern of 
LAIV vaccination is the possibility that it may give rise 
to wheezing and asthma attacks in children aged < 36 
months. For this reason, the CDC contraindicate the 
vaccination of FluMist® in children under 2 years and 
in those younger than 5 years with asthma or who have 
had one or more episodes of wheezing within the past 
year [49]. For the same reason, in 2011 the EMA rec-
ommended that marketing authorization be granted for 
LAIV (Fluenz®) in healthy individuals aged from 24 
months to 18 years [50]. Until 2006, only a few studies 
had been carried out on children with asthma [51]. In 
2006, however, Fleming et al. [52] published the results 
of a large trial in which the efficacy and safety of LAIV 
were compared with those of TIV in children (aged 
> 6 years) and adolescents (aged < 17 years) with asth-
ma. The study involved 1,111 subjects, who received the 
LAIV, and 1,109 subjects who received the TIV. The 
Authors concluded that the CAIV-T was well tolerated 
in children and adolescent with asthma, and that adverse 
pulmonary outcomes were not significantly more fre-
quent among CAIV-T recipients than TIV recipients.
Phenotypic and Genotypic Stability of LAIV, 
and Viral Shedding
Closely related with the safety of LAIV is the pheno-
typic and genetic stability of the attenuated strain.
To characterize genetic markers of attenuation, Maassab 
et al. drew up a set of genetic markers: growth of the 
cold-adapted strain at 25, 35 and 41°C, replication of the 
strain over different ranges of pH of the medium (5.7-6.3 
and 7.0-7.2), and characteristics of plaque formation in 
culture cells at 35 and 25°C. They also verified the avir-
ulence of the attenuated strain in ferrets and mice [9]. 
Similar techniques, particularly the plaque formation 
test, were also used to verify the attenuation of the Rus-
sian cold-adapted virus genetically [53].
The most important issue regarding the attenuated genes 
was their genetic stability; indeed, it was feared that the 
vaccine virus could revert to the wild type. In 1999, Cha 
et al. [54] carried out a genotyping study on 18 attenu-
ated strains isolated from secretions of 17 participants 
in a clinical trials, who had received the cold-adapted 
attenuated vaccine. Analysis of 11,800 nucleotides dem-
onstrated that, even after replication in human hosts, the 
cold-adapted strains remained stable [10, 54].
Another important issue regarding the attenuated strains 
was viral shedding, and thus the possibility of trans-
mission between vaccine recipients and close contacts. 
Viral shedding after the administration of cold-adapted 
attenuated vaccine has often been demonstrated, both in 
adults and in children. While the quantity of virus shed 
by adults is usually lower than the minimal infective 
dose [55], the issue is not completely clear with regard 
to children [2, 56]. However, a large study carried out on 
vaccinated children showed that transmission practically 
did not occur [10, 57].
Immunogenicity, efficacy and effectiveness
Smorodincev published a short review on the efficacy 
of Russian Live Influenza Vaccines (LIV) in 1969 [27]. 
The Author pointed out that, when the vaccine matched 
with circulating strains and when vaccinated subjects 
were properly studied, morbidity was clearly lower 
among the recipients of the cold-adapted vaccine than in 
a control group of volunteers.
In 1969, Maassab et al. administered cold-adapted at-
tenuated influenza vaccine to 10 volunteers [9]. Sero-
conversion was observed in two recipients who were 
seronegative before administration, and a 4-fold or 
more increase in HI titers was observed in subjects pre-
viously immunized (previously documented illness or 
vaccination) with the same strain contained in the vac-
cine.
A trial involving wild-type or cold-adapted influenza 
A/Alaska/6/77 virus strains was conducted by Murphy 
et al. [29]. In all of the groups studied, administration of 
the attenuated or the wild-type parent strain elicited an 
immunoresponse. However, the attenuated virus elicited 
a lesser immunoresponse than the wild-type strain.
The immunogenicity and protection provided by a re-
combinant obtained from an H3N2 strain (A/Victoria/75) 
and a cold-adapted donor A/Ann Arbor/6/60 (H2N2) 
were studied in healthy young adult males [58]. A se-
rum-neutralizing immunoresponse was elicited in 90% 
of vaccinees. Furthermore, the recipients of the attenu-
ated vaccine displayed significant protection in compar-
ison with unvaccinated.
In the 1996-1997 influenza season, Belshe et al. [40] con-
ducted a clinical trial using a cold-adapted, trivalent influ-
enza virus vaccine. One dose of vaccine or placebo was 
administered by intranasal spray to 288 children, while 
1,314 children received two doses 60 days apart. Children 
initially seronegative showed a 4-fold increase in anti-
body titers in 61-96% of cases, depending on the influenza 
strain. The volunteers were followed up for two influenza 
seasons. Influenza confirmed by cell-culture isolation was 
significantly more frequent in the placebo group than in 
the vaccine group (vaccine efficacy 93% [CI-95%: 88-
96%]). The vaccine was effective against 2 influenza wild 
strains (A-H3N2 and B) circulating in the 1996-97 win-
ter. The one-dose regimen displayed 89% efficacy and the 
two-dose regimen 94% efficacy.
Just before the authorization of Flumist®, Beyer et al. 
carried out a meta-analysis of 19 studies comparing a 
cold-adapted attenuated live influenza vaccine with in-
activated vaccine [38].
Regarding the immunoresponse against H3N2 viruses, in-
activated influenza vaccines (IIV) elicited twice as many 
antibodies as LIV; the immunoresponse to H1N1 strains 
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was similar, though slightly better for IIV. Only a few 
studies assessed secretory IgA. Although the literature 
on this issue was scant, the papers considered by Beyer 
et al. demonstrated a stronger IgA production by LIV re-
cipients than IIV recipients. The papers examined in the 
meta-analysis also included efficacy assessment through 
the virological follow-up of the volunteers, which was 
performed by isolating influenza virus in cell-cultures 
during the winter season. This evaluation showed that 
the protection conferred by the two vaccines was simi-
lar, though LIV yielded slightly better results than IIV. 
Regarding this last issue, Belshe et al. carried out a trial 
in children in 2004-05 [45]. They found fewer culture-
confirmed cases of influenza in the recipients of the live 
attenuated vaccine than in those who received inactivated 
vaccine (153 vs. 338 cases, p < 0.001). The superiority of 
the attenuated vaccine was confirmed on considering both 
antigenically well-matched and drifted viruses. Similar-
ly, in children (6-71 months) with recurrent respiratory 
tract infections, Ashkenazi et al. compared recipients of 
CAIV-T (n = 1,050) with recipients of TIV (1,035), and 
found that the attenuated vaccine displayed greater effi-
cacy than the inactivated vaccine [59].
On vaccinating children and adolescents with asthma 
(6-17 years of age), Fleming et al. also observed that 
CAIV-T conferred greater protection against communi-
ty-acquired culture-confirmed influenza than TIV [52].
Finally, an H1N1v pandemic live attenuated vaccine 
was evaluated by Mallory et al. [48] in children (H1N1v 
LAIV, n = 261; placebo, n = 65) and adults (H1N1v 
LAIV, n = 240; placebo, n = 60). After 2 administrations 
(28 days apart), LAIV displayed an immunogenicity 
profile similar to that of the previous seasonal live cold-
adapted influenza vaccine. Indeed, after 2 doses, serore-
sponse rates were 32% (vaccinees) vs. 14.5% (placebo 
recipients), and 14.9% (vaccinees) vs. 5.6% (placebo 
recipients) in adults and children, respectively.
Discussion
Live attenuated vaccines can significantly contribute to 
the control of seasonal and pandemic influenza episodes. 
However, the vaccine must have some important charac-
teristics. Obviously, it must be safe and effective. The 
genetic stability of attenuated strains and their possible 
transmission to contacts are closely related to safety. 
Several studies have demonstrated that vaccine viruses 
do not revert to wild-type virus [54, 55].
Other concerns regard the use of attenuated viruses in 
the elderly, in whom previous frequent contact with in-
fluenza viruses could determine an immune pressure and 
facilitate reversion to the wild type. Similarly, the use of 
a live vaccine to prevent a pandemic could generate new 
variants. However, if a reassortment of an attenuated vi-
rus and a wild pandemic strain occurred, the resulting re-
assortant would probably be less pathogenic in humans.
Another worry about live vaccines is safety. Since licen-
sure in the USA in 2003, General Practitioners (GPs) 
and nurses have considered safety concerns to be the 
foremost reason for the low acceptance of the vaccine. 
However, many of the doubts seem to stem from un-
proven fears and misperceptions rather than from recog-
nized figures [10].
Since LAIV has proved to be safe and effective, a wide-
spread use of this vaccine achieve better control of in-
fluenza among children, who are the first target of novel 
strains. Furthermore, children are important spreaders 
of wild viruses. Full acceptance of the live attenuated 
vaccine could provide further protection through herd 
immunity, as both the “Tecumseh Study” [60] and the 
Japanese experience [61] have demonstrated.
In addition, recent progress in genetic engineering could 
ameliorate the preparation of live influenza attenuated 
vaccines. Indeed, Jung et al. recently published a study 
on a useful method of preparing live attenuated influenza 
virus [62]. Using reverse genetics, these Authors were 
able to generate “6 + 2” influenza vaccine strains cor-
responding to A/Chicken/Korea/MS96 (H9N2) and A/
Indonesia/5/2005 (H5N1). Furthermore, Solorzano et al. 
used reverse genetics to generate a live-attenuated vaccine 
against the H1N1v pandemic strain. These Authors placed 
particular emphasis on the polymerase genes [63]. Re-
verse genetics is less laborious and less time-consuming 
than the traditional method of attenuation.
Once the high pathogenicity genes of the influenza 
strains are better known, reverse genetics will further 
improve the preparation of influenza vaccines. As yet, 
the molecular basis of virulence among influenza viruses 
is only partially recognized; for instance, it is known that 
the high pathogenicity of H5N1 strains is determined by 
basic amino acids at the cleavage site of hemagglutinin, 
and also by the presence of lysine (instead of glutamic 
acid) in position 627 of the PB2 protein coded by the 
corresponding gene [64].
In conclusion it can be asserted that:
• the safety profile of LAIV is well consolidated, 
and precautions must be taken only in infants (< 24 
months of age) and children under 5 years with a his-
tory of asthma;
• LAIV has been safely administered both to HIV-in-
fected children and adults [65, 66];
• the donor strains have excellent genetic stability;
• transmission to close contacts is practically non-ex-
istent;
• LAIV is well tolerated;
• the attenuated cold-adapted vaccine has been more 
effective than inactivated influenza vaccines in some 
circumstances in children [59];
• as LAIV also stimulates cellular immunity, it could 
help to reduce complications in infants and children;
• LAIV is also useful in preventing otitis media in chil-
dren [67];
• the nasal spray is clearly more acceptable than 
parenteral administration;
• LAIV stimulates local immunity, and probably pro-
vides broad cross-protection;
• the administration of LAIV is very flexible; Breiman 
et al. [68] recently demonstrated that LAIV could be 
co-administered with oral polio vaccines.
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